ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0493 • ACR Convergence 2020

    Automatic Joint Space Assessment in Hand Radiographs with Deep Learning Among Patients with Rheumatoid Arthritis

    Yun-Ju Huang1, Chang-Fu Kuo1, Fakai Wang2, Shun Miao2, Kang Zheng2 and Le Lu2, 1Chang Gung Memorial Hospital, Taoyuan, Taiwan (Republic of China), 2PAII labs, Bethesda, MD

    Background/Purpose: Assessment of joint space is the fundamental radiographic task to diagnose rheumatoid arthritis (RA) and to assess the severity and progression of the disease.…
  • Abstract Number: 0488 • ACR Convergence 2020

    Incidence of Dementia in Patients with Rheumatoid Arthritis and Association with DMARDs – Analysis of a National Claims Database

    Sebastian Sattui1, Iris Navarro-Millan2, Fenglong Xie3, Mangala Rajan2, Huifeng Yun4 and Jeffrey R Curtis4, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine, New York, 3University of Alabama at Birmingham, Birmingham, AL, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: There is growing interest regarding the role of neuroinflammation in the development of dementia and the potential role for anti-inflammatory therapy, including TNF-inhibitors (TNFi),…
  • Abstract Number: 0502 • ACR Convergence 2020

    Integration of Clinical and Protein Markers Through Machine Learning to Distinguish Patients with Psoriasis Arthritis from Those with Psoriasis Without Psoriatic Arthritis

    Sara Rahmati1, Fatima Abji1, Proton Rahman2 and Vinod Chandran3, 1University Health Network, Toronto, ON, Canada, 2Memorial University of Newfoundland, Department of Medicine, St John's, Canada, 3Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Psoriatic Arthritis (PsA) is a progressive inflammatory arthritis that occurs in about 24% of psoriasis patients. Early diagnosis of PsA is associated with better…
  • Abstract Number: 0501 • ACR Convergence 2020

    Structural Entheseal Lesions in Psoriasis Patients Are Associated with an Increased Risk Ofprogression to Psoriatic Arthritis – A Prospective Cohort Study

    David Simon1, Koray Tascilar1, Arnd Kleyer1, Sara Bayat2, Eleni Kampylafka2, Axel Hueber3, Juergen Rech1, Louis Schuster1, Klaus Engel4, Michael Sticherling2 and Georg Schett5, 1Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 3Sozialstiftung Bamberg, Sektion Rheumatologie, Bamberg, Germany, 4Siemens Healthcare GmbH Digital Technology & Camp; Innovation, SHS DS DTI, Erlangen, Germany, 5Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany

    Background/Purpose: We have previously reported that the presence of musculoskeletal pain in psoriasis patients is associated with a higher risk of developing psoriatic arthritis (PsA)…
  • Abstract Number: 0507 • ACR Convergence 2020

    Comparison of Secukinumab versus Adalimumab Efficacy by Sex in Psoriatic Arthritis from a Phase 3b, Double-blinded, Randomized, Active-controlled Study

    Grace Wright1, Peter Nash2, Laura Coates3, Jordi Gratacós4, Frank Behrens5, Kevin Ding6, Weibin Bao7, Luminita Pricop6, Corine Gaillez8 and Iain McInnes9, 1Association of Women in Rheumatology, New York, NY, 2School of Medicine Griffith University, Brisbane, Queensland, Australia, 3University of Oxford, Oxford, United Kingdom, 4University Hospital Parc Tauli Sabadell, Barcelona, Spain, 5CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, 6Novartis Pharmaceuticals Corporation, East Hanover, 7Novartis Pharmaceuticals Corporation, East Hannover, 8Novartis Pharma AG, Basel, Switzerland, 9Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Lower efficacy to anti-tumor necrosis factor treatment has been reported in female patients with psoriatic arthritis (PsA) as compared to males in clinical registries.1…
  • Abstract Number: 0506 • ACR Convergence 2020

    Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through Week 52 of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis

    Iain McInnes1, Proton Rahman2, Alice Gottlieb3, Elizabeth Hsia4, Alexa Kollmeier5, Xie Xu6, Ramanand Subramanian7, Prasheen Agarwal7, Shihong Sheng7, Yusang Jiang7, Bei Zhou7, Désirée van der Heijde8 and Philip Mease9, 1Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Memorial University of Newfoundland, Department of Medicine, St John's, Canada, 3Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 4Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, 5Janssen Research & Development, LLC, La Jolla, CA, 6Janssen Research & Development, LLC, San Marcos, CA, 7Janssen Research & Development, LLC, Spring House, PA, 8Leiden University Medical Center, Leiden, Netherlands, 9Seattle Rheumatology Associates, P.L.L.C., Seattle, WA

    Background/Purpose: Guselkumab (GUS), a monoclonal antibody that specifically binds to the p19-subunit of IL-23, is approved to treat psoriasis. Through Week24 (W24) of the Ph3,…
  • Abstract Number: 0512 • ACR Convergence 2020

    Efficacy of Apremilast for the Treatment of Manifestations of Behçet’s Syndrome Other Than Oral Ulcers, Including Skin Lesions and Arthritis

    Gülen Hatemi1, Alfred Mahr2, Mitsuhiro Takeno3, Doyoung Kim4, Melike Melikoğlu1, Sue Cheng5, Sven Richter5, Michele Brunori6, Maria Paris5, Mindy Chen5 and Yusuf Yazici7, 1Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, Istanbul, Turkey, 2Cantonal Hospital St. Gallen, St. Gallen, Switzerland, 3Nippon Medical School, Graduate School of Medicine, Tokyo, Japan, 4Yonsei University College of Medicine and Severance Hospital, Seoul, Republic of Korea, 5Amgen Inc., Thousand Oaks, 6Amgen Europe GmbH, Rotkreuz, Switzerland, 7New York University School of Medicine, New York

    Background/Purpose: Behçet’s syndrome is a chronic, multi-system inflammatory disorder characterized by painful and recurrent oral ulcers (OU) and other manifestations, such as skin lesions and…
  • Abstract Number: 0514 • ACR Convergence 2020

    Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor the Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Observational Cohort Study

    Kaitlin Quinn1, Himanshu Dashora2, Mark Ahlman3, Elaine Novakovich2 and Peter C. Grayson2, 1Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, 2Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, 3National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD

    Background/Purpose: Two randomized controlled trials have demonstrated the clinical efficacy of tocilizumab for treatment of giant cell arteritis (GCA) (1,2).  In these trials, response to…
  • Abstract Number: 0509 • ACR Convergence 2020

    Classification of Patients with Relapsing Polychondritis Based on Somatic Mutations in UBA1

    Marcela Ferrada1, Keith Sikora2, Sinisa Savic3, Yiming Luo4, Kristina Wells5, Emily Rose1, Kaitlin Quinn6, Wendy Goodspeed1, Anne Jones7, Mimi Le8, Amanda Ombrello9, Zuoming Deng10, Massimo Gadina11, Wanxia Tsai12, Ivona Aksentijevich7, Daniel Kastner13, David Beck14 and Peter C. Grayson15, 1Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2National Institutes of Health Clinical Center, Bethesda, MD, 3University of Leeds, England, United Kingdom, 4Rheumatology Fellowship and Training Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, 5Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, 6Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, 7National Human Genome Research Institute, Bethesda, MD, 8Oregon Health & Science University, Portland, 9National Institutes of Health, Bethesda, 10National Institute of Arthritis Musculoskeletal and Skin diseases, Bethesda, 11National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, 12National Institute of Arthritis Musculoskeletal and Skin diseases, Bethesda, MD, 13National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD, 14National Human Genome Research Institute, Bethesda, 15Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD

    Background/Purpose: Relapsing polychondritis (RP) is a rare, heterogenous, systemic inflammatory disease with a predilection for cartilaginous structures. Recently we discovered myeloid-restricted somatic mutations in UBA1 in…
  • Abstract Number: 0504 • ACR Convergence 2020

    Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial

    Mark Genovese1, Apinya Lertratanakul2, Jaclyn K Anderson2, Kim Papp3, William Tillett4, Filip Van den Bosch5, Shigeyoshi Tsuji6, Eva Dokoupilova7, Mauro Keiserman8, Xin Wang2, Sheng Zhong2, Patrick Zueger2, Aileen Pangan9 and Philip Mease10, 1Stanford University Medical Center, Palo Alto, CA, 2AbbVie Inc., North Chicago, IL, 3Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, 4Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, 5Ghent University Hospital, Ghent, Belgium, 6Department of Orthopaedics/Rheumatology, National Hospital Organization, Osaka Minami Medical Center, Osaka, Japan, 7Uherske Hradiste and University of Veterinary and Pharmaceutical Sciences,, Brno, Czech Republic, 8Pontificial Catholic University, Porto Alegre, Brazil, 9Abbvie Inc., La Grange, IL, 10Seattle Rheumatology Associates, P.L.L.C., Seattle, WA

    Background/Purpose: Upadacitinib (UPA) is an oral, reversible, JAK inhibitor approved for treatment of moderate to severe rheumatoid arthritis (RA) and currently under evaluation for treatment…
  • Abstract Number: 0517 • ACR Convergence 2020

    Trends in the Incidence and Use of Diagnostic Modalities for Giant Cell Arteritis over Seven Decades: A Population-based Study

    Thomas Garvey1, Cynthia Crowson2, Matthew J. Koster3 and Kenneth Warrington3, 1Mayo Clinic Rochester, Apple Valley, MN, 2Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, 3Mayo Clinic, Rochester, MN

    Background/Purpose: Diagnostic methods for giant cell arteritis (GCA) have evolved over recent decades, and large vessel imaging plays an increasing role in disease detection.   The…
  • Abstract Number: 0520 • ACR Convergence 2020

    Antiphospholipid Antibodies and Thrombotic Events in COVID-19 Patients Hospitalized in Medicine Ward

    Alexandre Le Joncour1, Corinne Frere1, Isabelle Martin-Toutain1, Paul Gougis1, Pascale Ghillani-Dalbin1, Georgina Maalouf1, Matheus Vieira1, Anne-Genevieve Marcelin1, Joe-Elie Salem1, Yves Allenbach2, David Saadoun3, Olivier Benveniste4 and Patrice Cacoub1, 1APHP, paris, France, 2Sorbonne Université, Paris, Ile-de-France, France, 3AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Centre national de références Maladies Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares, PAris, France, 4Sorbonne Université, paris, France

    Background/Purpose: A high prevalence of thrombotic events has been reported in critically ill COVID-19 patients but data on the prevalence of thrombosis in ward patients…
  • Abstract Number: 0521 • ACR Convergence 2020

    Avoiding Misclassification of Primary Antiphospholipid Syndrome as Systemic Lupus Erythematosus: What Are the Best-performing SLE Classification Criteria?

    Flavio Signorelli1, Gustavo Balbi2, Eloisa Bonfa3, Eduardo Borba4 and Danieli Andrade5, 1Universidade de São Paulo, Rio de janeiro, Rio de Janeiro, Brazil, 2Universidade de São Paulo, Juiz de Fora, Minas Gerais, Brazil, 3Hospital das Clínicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 5University of Sao Paulo, Sao Paulo, Brazil

    Background/Purpose: Primary Antiphospholipid Syndrome (PAPS) patients, when submitted to Systemic Lupus Erythematosus (SLE) classification criteria, can be misclassified. The new 2019 ACR/EULAR classification criteria have…
  • Abstract Number: 0516 • ACR Convergence 2020

    Characteristics of Giant Cell Arteritis Flares After Successful Treatment with Tocilizumab: Results from the Long-Term Extension of a Randomized Controlled Phase 3 Trial

    Sebastian Unizony1, Shalini V. Mohan2, Jian Han2 and John H. Stone1, 1Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 2Genentech, South San Francisco, CA

    Background/Purpose: To investigate the characteristics of disease flare after successful treatment with tocilizumab (TCZ) in patients with giant cell arteritis (GCA).Methods: We performed a post…
  • Abstract Number: 0524 • ACR Convergence 2020

    Determination of Homogenous Subgroups of Antiphospholipid Syndrome: A Cluster Analysis Based on 509 Cases

    Yann Nguyen1, Cécile Yelnik2, Nathalie Morel3, Romain Paule4, Pierre-Yves Hatron2, Romain Stammler5, Léo Plaçais3, Jean-Charles Piette6, Luc Mouthon7, Eric Hachulla8, Marc Lambert2, Le Guern Véronique3 and Nathalie Costedoat-Chalumeau9, 11Department of Internal Medicine, Hôpital Beaujon, APHP Nord, Université de Paris, Clichy, Clichy, France, 2Department of Internal Medicine and Clinical Immunology, National Referral Centre for rare Systemic Auto-immune Diseases North and North-West of France (CeRAINO), CHU Lille, Hôpital Claude Huriez, Lille, France, Lille, France, 3National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France, Paris, France, 4Department of Internal Medicine, Hôpital Foch, Suresnes, France, Suresnes, France, 5National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France, Paris, 6Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, 7National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, 8Department of Internal Medicine and Clinical Immunology, Université de Lille, Lille, France, Lille, France, 9APHP, Université de Paris, Paris, France

    Background/Purpose: Antiphospholipid syndrome (APS) is a heterogeneous disease, with different phenotypes which may widely vary from classical thrombotic or obstetrical manifestations to catastrophic antiphospholipid syndrome…
  • « Previous Page
  • 1
  • …
  • 659
  • 660
  • 661
  • 662
  • 663
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology